expansion
AstraZeneca Invests $135M in Swedish Biologics Manufacturing Expansion
AstraZeneca, biologics manufacturing, Sweden, expansion, investment
Aadi Bioscience Cuts 80% of R&D Staff Amid Fyarro Expansion Setbacks
Aadi Bioscience, R&D workforce, Fyarro, expansion efforts, layoffs, pharmaceutical industry
Incyte Seeks Expanded Approval for Monjuvi Following Successful Phase III Trial in Follicular Lymphoma
Incyte, Monjuvi, follicular lymphoma, Phase III trial, label expansion, tafasitamab, MorphoSys, FDA approval, cancer treatment.
Novo Nordisk Withdraws FDA Submission for Wegovy’s Heart Failure Indication, Plans to Reapply Next Year
Novo Nordisk, Wegovy, FDA submission, heart failure, label expansion, regulatory delay
BioMarin’s Brineura Receives Significant Label Expansion from FDA for Children Under 3 with CLN2 Disease
BioMarin, Brineura, FDA, Label Expansion, CLN2 Disease, Children Under 3, Cerliponase Alfa, Intraventricular Injection, Motor Ability Deterioration, Neurodegenerative Symptoms
Grünenthal Acquires US-Based Valinor Pharma for $250 Million
Grünenthal, Valinor Pharma, acquisition, Movantik, naloxegol, opioid-induced constipation, pain management, US market expansion, pharmaceutical industry
Grünenthal Expands US Presence with $250 Million Acquisition of Valinor Pharma and Movantik
Grünenthal, Valinor Pharma, Movantik, Acquisition, US Expansion, Pharmaceutical Industry
CordenPharma Invests €900M in Peptide Manufacturing Expansion to Meet Rising Demand for GLP-1 Medications
CordenPharma, GLP-1, peptide manufacturing, expansion, investment, diabetes, obesity, pharmaceutical industry
Lilly’s Zepbound Shows Promise in Resolving Sleep Apnea in Obese Patients, Strengthening Case for Label Expansion
Zepbound, tirzepatide, sleep apnea, obesity, label expansion, Eli Lilly, SURMOUNT-OSA program, weight loss, FDA approval
Amylyx Acquires GLP-1 Receptor Antagonist for $35M to Fill Pipeline Gap
Amylyx Pharmaceuticals, Relyvrio, GLP-1 receptor antagonist, Eiger Biopharma, pipeline expansion, ALS, Wolfram syndrome